1
|
Linard C, Lasne-Cardon A, Salaun V, Rousselot P, Dorbeau M. [Composite lymphoma: Case report of a coexisting follicular and mantle cell lymphoma in situ in a cervical node]. Ann Pathol 2021; 42:177-182. [PMID: 34949480 DOI: 10.1016/j.annpat.2021.11.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2021] [Revised: 11/18/2021] [Accepted: 11/25/2021] [Indexed: 11/19/2022]
Abstract
Composite lymphoma represents 1-4% of lymphomas. Only 8 case reports concerned coexisting follicular lymphoma and mantle cell lymphoma. Here, we report the case of an 81 years old man who has been diagnosed with a composite follicular and in situ mantle cell lymphoma. The use of a large panel of immunohistochemical stains associated with the flow cytometry results have allowed us to make this particular diagnosis. We highlight here a common clonal origin of the composite lymphoma's two entities, as described in previous publications.
Collapse
Affiliation(s)
- Camille Linard
- Service d'anatomie pathologique, Centre François-Baclesse, 3, avenue du Général Harris, 14000 Caen, France.
| | - Audrey Lasne-Cardon
- Service d'ORL et de chirurgie cervico-faciale, Centre François-Baclesse, 3, avenue du Général Harris, 14000 Caen, France
| | - Véronique Salaun
- Service d'hématologie biologique, Centre hospitalier universitaire de Caen Normandie, avenue de la côte de Nacre, 14000 Caen, France
| | - Pierre Rousselot
- Service d'anatomie pathologique, Centre François-Baclesse, 3, avenue du Général Harris, 14000 Caen, France
| | - Marine Dorbeau
- Service d'anatomie pathologique, Centre François-Baclesse, 3, avenue du Général Harris, 14000 Caen, France
| |
Collapse
|
2
|
Zalmaï L, Viailly PJ, Biichle S, Cheok M, Soret L, Angelot-Delettre F, Petrella T, Collonge-Rame MA, Seilles E, Geffroy S, Deconinck E, Daguindau E, Bouyer S, Dindinaud E, Baunin V, Le Garff-Tavernier M, Roos-Weil D, Wagner-Ballon O, Salaun V, Feuillard J, Brun S, Drenou B, Mayeur-Rousse C, Okamba P, Dorvaux V, Tichionni M, Rose J, Rubio MT, Jacob MC, Raggueneau V, Preudhomme C, Saas P, Ferrand C, Adotevi O, Roumier C, Jardin F, Garnache-Ottou F, Renosi F. Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape. Haematologica 2020; 106:3056-3066. [PMID: 33054115 PMCID: PMC8634182 DOI: 10.3324/haematol.2020.253740] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2020] [Indexed: 11/09/2022] Open
Abstract
Neoplasms involving plasmacytoid Dendritic Cells (pDCs) include Blastic pDC Neoplasms (BPDCN) and other pDC proliferations, where pDCs are associated with myeloid malignancies: most frequently Chronic MyeloMonocytic Leukemia (CMML) but also Acute Myeloid Leukemia (AML), hereafter named pDC-AML. We aimed to determine the reactive or neoplastic origin of pDCs in pDC-AML, and their link with the CD34+ blasts, monocytes or conventional DCs (cDCs) associated in the same sample, by phenotypic and molecular analyses (targeted NGS, 70 genes). We compared 15 pDC-AML at diagnosis with 21 BPDCN and 11 normal pDCs from healthy donors. CD45low CD34+ blasts were found in all cases (10-80% of medullar cells), associated with pDCs (4-36%), monocytes in 14 cases (1-10%) and cDCs (2 cases, 4.8-19%). pDCs in pDC-AML harbor a clearly different phenotype from BPDCN: CD4+ CD56- in 100% of cases, most frequently CD303+, CD304+ and CD34+; lower expression of cTCL1 and CD123 with isolated lymphoid markers (CD22/CD7/CD5) in some cases, suggesting a pre-pDC stage. In all cases, pDCs, monocytes and cDC are neoplastic since they harbor the same mutations as CD34+ blasts. RUNX1 is the most commonly mutated gene: detected in all AML with minimal differentiation (M0-AML) but not in the other cases. Despite low number of cases, the systematic association between M0-AML, RUNX1 mutations and an excess of pDC is puzzling. Further evaluation in a larger cohort is required to confirm RUNX1 mutations in pDC-AML with minimal differentiation and to investigate whether it represents a proliferation of blasts with macrophage and DC progenitor potential.
Collapse
Affiliation(s)
- Loria Zalmaï
- Service d'hématologie biologique, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris
| | | | - Sabeha Biichle
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon
| | - Meyling Cheok
- INSERM U837, CHRU Lille, IRCL Laboratoire d'Hématologie, Centre de Biologie Pathologie, Lille
| | - Lou Soret
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon
| | - Fanny Angelot-Delettre
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon
| | - Tony Petrella
- Department of Pathology, University of Montréal, Hôpital Maisonneuve-Rosemont, Montréal, QC
| | | | - Estelle Seilles
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon
| | - Sandrine Geffroy
- INSERM U837, CHRU Lille, IRCL Laboratoire d'Hématologie, Centre de Biologie Pathologie, Lille, France; Laboratoire d'Hématologie A, Centre de Biologie Pathologie, Boulevard du Pr Leclercq, 59037 Lille
| | | | | | - Sabrina Bouyer
- Service d'Hématologie biologique, CHU La Milétrie, Poitiers
| | | | - Victor Baunin
- Laboratoire du Groupe Hospitalier de La Rochelle-Ré-Aunis, CH de La Rochelle, La Rochelle
| | - Magali Le Garff-Tavernier
- Laboratoire d'Hématologie, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris
| | - Damien Roos-Weil
- Service d'Hématologie Clinique, Sorbonne Université, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris
| | - Orianne Wagner-Ballon
- Département d'Hématologie biologique, Hôpitaux Universitaires Henri Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Créteil
| | - Véronique Salaun
- Laboratoire d'Hématologie, CHU de Caen Normandie, Normandie Université, UNICAEN, Caen
| | - Jean Feuillard
- Laboratoire d'hématologie, CHU Dupuytren, avenue Martin Luther King, Limoges
| | - Sophie Brun
- Laboratoire d'Hématologie et Consultations d'Hématologie Biologique, Hôpital Universitaire Carémeau, Nîmes
| | - Bernard Drenou
- Service d'Hématologie, Groupe Hospitalier de la région Mulhouse Sud Alsace, Mulhouse
| | | | - Patricia Okamba
- Laboratoire d'hématologie et auto-immunité, Hôpital de Mercy, CHR de Metz-Thionville
| | | | | | - Johann Rose
- Laboratoire d'hématologie, CH du Mans, Le Mans
| | - Marie Thérèse Rubio
- Service Hématologie, CNRS UMR7365, Biopôle Université de Lorraine, CHRU Nancy, Vandœuvre-lès-Nancy
| | | | - Victoria Raggueneau
- Service de Biologie Médicale, Centre Hospitalier de Versailles A. Mignot, Le Chesnay
| | - Claude Preudhomme
- INSERM U837, CHRU Lille, IRCL Laboratoire d'Hématologie, Centre de Biologie Pathologie, Lille, France; Laboratoire d'Hématologie A, Centre de Biologie Pathologie, Boulevard du Pr Leclercq, 59037 Lille
| | - Philippe Saas
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon
| | - Christophe Ferrand
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon
| | - Olivier Adotevi
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon
| | - Christophe Roumier
- INSERM U837, CHRU Lille, IRCL Laboratoire d'Hématologie, Centre de Biologie Pathologie, Lille, France; Laboratoire d'Hématologie A, Centre de Biologie Pathologie, Boulevard du Pr Leclercq, 59037 Lille
| | | | - Francine Garnache-Ottou
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon.
| | - Florian Renosi
- Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon
| |
Collapse
|
3
|
Joly E, Rimond O, Salaun V, Comoz F, Morice C, Dompmartin A, Verneuil L. [Localized urticarial rituximab-induced reaction in primary cutaneous marginal zone B-cell lymphoma]. Ann Dermatol Venereol 2019; 147:50-52. [PMID: 31635943 DOI: 10.1016/j.annder.2019.09.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2018] [Revised: 04/02/2019] [Accepted: 09/04/2019] [Indexed: 11/26/2022]
Affiliation(s)
- E Joly
- Service de dermatologie, CHU de Caen, avenue de la Côte-de-Nacre, 14033 Caen, France; Université de Caen Normandie, Medical School, 14000 Caen, France.
| | - O Rimond
- Service de dermatologie, CHU de Caen, avenue de la Côte-de-Nacre, 14033 Caen, France
| | - V Salaun
- Service d'hématologie biologique, CHU de Caen, 14033 Caen, France
| | - F Comoz
- Service d'anatomie pathologie, CHU de Caen, 14033 Caen, France
| | - C Morice
- Service de dermatologie, CHU de Caen, avenue de la Côte-de-Nacre, 14033 Caen, France
| | - A Dompmartin
- Service de dermatologie, CHU de Caen, avenue de la Côte-de-Nacre, 14033 Caen, France; Université de Caen Normandie, Medical School, 14000 Caen, France
| | - L Verneuil
- Service de dermatologie, CHU de Caen, avenue de la Côte-de-Nacre, 14033 Caen, France
| |
Collapse
|
4
|
Delehaye F, Villarbu M, Salaun V, Bracquemart C, Goyer I, Bodet D. Psychiatric manifestation and pancytopenia during a sickle cell vaso-occlusive crisis: An unusual etiology. Pediatr Blood Cancer 2019; 66:e27758. [PMID: 31006965 DOI: 10.1002/pbc.27758] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/19/2019] [Revised: 03/25/2019] [Accepted: 03/26/2019] [Indexed: 11/07/2022]
Affiliation(s)
- Fanny Delehaye
- Department of Pediatric Hematology and Oncology, University Hospital of Caen, Caen, France
| | | | - Véronique Salaun
- Laboratory of Hematology, University Hospital of Caen, Caen, France
| | | | - Isabelle Goyer
- Department of Pharmacy, University Hospital of Caen, Caen, France
| | - Damien Bodet
- Department of Pediatric Hematology and Oncology, University Hospital of Caen, Caen, France
| |
Collapse
|
5
|
Solly F, Angelot-Delettre F, Ticchioni M, Geneviève F, Rambaud H, Baseggio L, Plesa A, Debliquis A, Garnache-Ottou F, Roggy A, Campos L, Aanei C, Rosenthal-Allieri A, Georget MT, Lachot S, Jacob MC, Robillard N, Wuilleme S, Andre-Kerneis E, Cornet E, Salaun V, Bennami H, Lhoumeau AC, Arnoulet C, Jacqmin H, Neyman N, Latger-Cannard V, Massin F, Lainey E, Le Garff-Tavernier M, Costopoulos M, Roussel M, Mayeur-Rousse C, Eischen A, Raggeneau V, Derrieux C, Maurer M, Asnafi V, Trinquand A, Brouzes C, Lhermitte L. Standardization of Flow Cytometric Immunophenotyping for Hematological Malignancies: The FranceFlow Group Experience. Cytometry A 2019; 95:1008-1018. [PMID: 31364809 DOI: 10.1002/cyto.a.23844] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2018] [Revised: 06/04/2019] [Accepted: 06/05/2019] [Indexed: 01/25/2023]
Abstract
Flow cytometry is broadly used for the identification, characterization, and monitoring of hematological malignancies. However, the use of clinical flow cytometry is restricted by its lack of reproducibility across multiple centers. Since 2006, the EuroFlow consortium has been developing a standardized procedure detailing the whole process from instrument settings to data analysis. The FranceFlow group was created in 2010 with the intention to educate participating centers in France about the standardized instrument setting protocol (SOP) developed by the EuroFlow consortium and to organise several rounds of quality controls (QCs) in order to evaluate the feasibility of its application and its results. Here, we report the 5 year experience of the FranceFlow group and the results of the seven QCs of 23 instruments, involving up to 19 centers, in France and in Belgium. The FranceFlow group demonstrates that both the distribution and applicability of the SOP have been successful. Intercenter reproducibility was evaluated using both normal and pathological blood samples. Coefficients of variation (CVs) across the centers were <7% for the percentages of cell subsets and <30% for the median fluorescence intensities (MFIs) of the markers tested. Intracenter reproducibility provided similar results with CVs of <3% for the percentages of the majority of cell subsets, and CVs of <20% for the MFI values for the majority of markers. Altogether, the FranceFlow group show that the 19 participating labs might be considered as one unique laboratory with 23 identical flow cytometers able to reproduce identical results. Therefore, SOP significantly improves reproducibility of clinical flow in hematology and opens new avenues by providing a robust companion diagnostic tool for clinical trials in hematology. © 2019 International Society for Advancement of Cytometry.
Collapse
Affiliation(s)
- Françoise Solly
- CHU de St Etienne, Laboratoire d'hématologie, Saint-Etienne, France.,CHU Vaudois-Lausanne, Laboratoire d'hématologie, Lausanne, Switzerland
| | - Fanny Angelot-Delettre
- Etablissement Francais du Sang Bourgogne Franche-Comte, laboratoire d'hématologie, F-25000, Besançon, France.,Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000, Besançon, France
| | | | - Franck Geneviève
- CHU Angers, Laboratoire d'Hématologie Fédération Hospitalo-Universitaire GOAL, Grand Ouest Against Leukemia, Angers, France
| | - Hubert Rambaud
- CHU Angers, Laboratoire d'Hématologie Fédération Hospitalo-Universitaire GOAL, Grand Ouest Against Leukemia, Angers, France
| | - Lucile Baseggio
- Centre Hospitalier Lyon Sud Hospices civils de Lyon, Laboratoire d'hématologie, Lyon, France
| | - Adriana Plesa
- Centre Hospitalier Lyon Sud Hospices civils de Lyon, Laboratoire d'hématologie, Lyon, France
| | - Agathe Debliquis
- Groupe Hospitalier de la région Mulhouse sud Alsace, Laboratoire d'Hématologie, Mulhouse, France
| | - Francine Garnache-Ottou
- Etablissement Francais du Sang Bourgogne Franche-Comte, laboratoire d'hématologie, F-25000, Besançon, France.,Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F-25000, Besançon, France
| | - Anne Roggy
- Etablissement Francais du Sang Bourgogne Franche-Comte, laboratoire d'hématologie, F-25000, Besançon, France
| | - Lydia Campos
- CHU de St Etienne, Laboratoire d'hématologie, Saint-Etienne, France
| | - Carmen Aanei
- CHU de St Etienne, Laboratoire d'hématologie, Saint-Etienne, France
| | | | | | | | | | | | | | | | - Edouard Cornet
- CHU Caen, Laboratoire d'Hématologie; INSERM U1245, Group Biomarkers of lymphoma and solid Tumors Equipe MICAH, Caen, France
| | - Véronique Salaun
- Centre Hospitalier Universitaire de Caen, Laboratoire d'hématologie, Caen, France
| | - Hind Bennami
- Institut Curie, Laboratoire d'hématologie, Saint-Cloud, France
| | | | - Christine Arnoulet
- Institut Paoli-Calmettes, Département de Biologie du cancer, Institut Paoli-Calmettes, Département de Biologie du cancer, Marseille, France
| | - Hugues Jacqmin
- CHU UCL Namur, Laboratoire d'Hématologie, Namur, Belgium
| | - Nicolas Neyman
- CHU UCL Namur, Laboratoire d'Hématologie, Namur, Belgium
| | | | - Fredéric Massin
- Centre Hospitalier Universitaire de Nancy, Plateforme de cytometrie en flux, Nancy, France
| | - Elodie Lainey
- Hôpital Robert Debré- APHP, Service d'Hématologie Biologique, Hôpital Robert Debré- APHP, UMRS_1131- Institut Universitaire d'Hématologie, Paris, France
| | - Magali Le Garff-Tavernier
- Groupe Hospitalier Pitié-Salpêtrière, UF Phénotypage des Hémopathies, Centre d'Ecologie Cellulaire, Service d'hématologie Biologique, Paris, France
| | - Myrto Costopoulos
- Groupe Hospitalier Pitié-Salpêtrière, UF Phénotypage des Hémopathies, Centre d'Ecologie Cellulaire, Service d'hématologie Biologique, Paris, France.,INSERM U1138, Programmed Cell Death and Physiopathology of Tumor Cells Centre de recherche des cordeliers, Paris, France
| | | | | | - Alice Eischen
- CHU Strasbourg, Laboratoire d'hématologie, Strasbourg, France
| | - Victoria Raggeneau
- CH Versailles, Service de biologie médicale, Unité d'hématologie et de cytogénétique onco hématologique, Versailles, France
| | - Coralie Derrieux
- Grand Hôpital de l'Est Francilien, Laboratoire d'Hématologie, Meaux, France
| | - Maxime Maurer
- Hôpitaux Civils de Colmar, Laboratoire d'Hématologie, Colmar, France
| | - Vahid Asnafi
- Université Paris Descartes Sorbonne Cité, Institut Necker-Enfants Malades (INEM), Institut National de recherche Médicale (INSERM) U1151, Paris, France.,Hôpital Necker Enfants-Malades, Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Amélie Trinquand
- Université Paris Descartes Sorbonne Cité, Institut Necker-Enfants Malades (INEM), Institut National de recherche Médicale (INSERM) U1151, Paris, France.,Hôpital Necker Enfants-Malades, Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Chantal Brouzes
- Université Paris Descartes Sorbonne Cité, Institut Necker-Enfants Malades (INEM), Institut National de recherche Médicale (INSERM) U1151, Paris, France.,Hôpital Necker Enfants-Malades, Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| | - Ludovic Lhermitte
- Université Paris Descartes Sorbonne Cité, Institut Necker-Enfants Malades (INEM), Institut National de recherche Médicale (INSERM) U1151, Paris, France.,Hôpital Necker Enfants-Malades, Laboratory of Onco-Hematology, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
| |
Collapse
|
6
|
Reboursiere E, Gac AC, Garnier A, Salaun V, Reman O, Pham AD, Cabrera Q, Khoy K, Vilque JP, Fruchart C, Chantepie S, Johnson-Ansah H, Macro M, Cheze S, Benabed K, Mear JB, Troussard X, Damaj G, Le Mauff B, Toutirais O. Increased frequencies of circulating and tumor-resident Vδ1 + T cells in patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2017; 59:187-195. [PMID: 28562153 DOI: 10.1080/10428194.2017.1321751] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Gamma-delta (γδ) T cells contribute to the innate immune response against cancer. In samples of 20 patients upon DLBCL diagnosis, we found that Vδ1+ T cells were the major γδ T cell subset in tumors and PBMCs of patients, while Vδ2 T cells were preponderant in PBMCs of healthy subjects. Interestingly, the germinal center (GC) subtype was associated with an increase in Vδ1+ T cells in tumors, whereas the non-GC subtype was associated with a lower frequency of γδ T cells. While circulating Vδ1+ T cells of patients or HSs mostly exhibited a naïve phenotype, the majority of tumor Vδ1+ T cells showed a central memory phenotype. Resident or circulating γδ T cells from patients were not functionally impaired since they produced high levels of IFN-γ. Collectively, our findings are in favor of γδ T cell activation in tumors and open new perspectives for their modulation in DLBCL immunotherapy.
Collapse
Affiliation(s)
- Emilie Reboursiere
- a Department of Clinical Hematology , CHU de Caen , Caen , France.,b Normandie University, UNICAEN, INSERM U919, Sérine Protéases et Physiopathologie de l'unité Neurovasculaire , Caen , France
| | - Anne-Claire Gac
- a Department of Clinical Hematology , CHU de Caen , Caen , France
| | - Anthony Garnier
- b Normandie University, UNICAEN, INSERM U919, Sérine Protéases et Physiopathologie de l'unité Neurovasculaire , Caen , France
| | - Véronique Salaun
- c Department of Hemato-Biology , University Hospital of Caen , Caen , France
| | - Oumedaly Reman
- a Department of Clinical Hematology , CHU de Caen , Caen , France
| | - Anne-Dominique Pham
- d Department of Biostatistics and Clinical Research , University Hospital of Caen , Caen , France
| | - Quentin Cabrera
- a Department of Clinical Hematology , CHU de Caen , Caen , France
| | - Kathy Khoy
- e Department of Immunology , University Hospital of Caen , Caen , France
| | | | | | | | | | - Margaret Macro
- a Department of Clinical Hematology , CHU de Caen , Caen , France
| | - Stéphane Cheze
- a Department of Clinical Hematology , CHU de Caen , Caen , France
| | - Khaled Benabed
- a Department of Clinical Hematology , CHU de Caen , Caen , France
| | | | - Xavier Troussard
- c Department of Hemato-Biology , University Hospital of Caen , Caen , France
| | - Gandhi Damaj
- a Department of Clinical Hematology , CHU de Caen , Caen , France
| | - Brigitte Le Mauff
- b Normandie University, UNICAEN, INSERM U919, Sérine Protéases et Physiopathologie de l'unité Neurovasculaire , Caen , France.,e Department of Immunology , University Hospital of Caen , Caen , France
| | - Olivier Toutirais
- b Normandie University, UNICAEN, INSERM U919, Sérine Protéases et Physiopathologie de l'unité Neurovasculaire , Caen , France.,e Department of Immunology , University Hospital of Caen , Caen , France
| |
Collapse
|
7
|
Nascimbeni C, Chantepie S, Brugiere C, Comoz F, Salaun V, Verneuil L. [Cutaneous involvement in T-lymphoblastic lymphoma]. Ann Dermatol Venereol 2017; 144:268-274. [PMID: 28242092 DOI: 10.1016/j.annder.2017.01.001] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2016] [Revised: 09/27/2016] [Accepted: 01/13/2017] [Indexed: 12/19/2022]
Abstract
BACKGROUND Lymphoblastic lymphoma (LBL) is a rare form of non-Hodgkin's lymphoma (NHL). Cutaneous LBL is seen in less than 20% of patients. PATIENTS AND METHODS Herein, we report the case of a 66-year-old male patient without any previous disease history of note and who was presenting a gradually spreading tumoral lesion of the scalp, several purplish macules and nodules on the trunk, and a single spinal adenopathy. A thoracic-abdominal-pelvic CT scan performed for acute renal failure, revealed extensive infiltration of retroperitoneal tissue. Skin biopsies and staging tests indicated LBL-T with associated cutaneous, bone and lymph node retroperitoneal lesions with no mediastinal mass. After two months of treatment with CHOP (four courses), the cutaneous lesions and abdominal tumoral mass had regressed and renal function had returned to normal. DISCUSSION There have been 13 reported cases of LBL with cutaneous involvement; most of these patients were young (under 30 years) and presented multiple cutaneous lesions (nodules or tumors) associated with numerous peripheral adenopathies, invasion of the bone marrow, and in many cases, a mediastinal mass. The clinical presentation of LBL-T in our case is novel on account of the cutaneous sites, associated with abdominal tumoral syndrome, without mediastinal infiltration, and with a single peripheral adenopathy, in an elderly subject.
Collapse
Affiliation(s)
- C Nascimbeni
- Service de dermatologie, CHU de Caen, avenue de la Côte-de-Nacre, 14033 Caen, France; Université de Caen Normandie, 14000 Caen, France.
| | - S Chantepie
- Service d'hématologie clinique, CHU de Caen, 14033 Caen, France; Université de Caen Normandie, 14000 Caen, France
| | - C Brugiere
- Service de dermatologie, CHU de Caen, avenue de la Côte-de-Nacre, 14033 Caen, France; Université de Caen Normandie, 14000 Caen, France
| | - F Comoz
- Service d'anatomie pathologique, CHU de Caen, 14033 Caen, France; Université de Caen Normandie, 14000 Caen, France
| | - V Salaun
- Service d'hématologie biologique, CHU de Caen, 14033 Caen, France; Université de Caen Normandie, 14000 Caen, France
| | - L Verneuil
- Service de dermatologie, CHU de Caen, avenue de la Côte-de-Nacre, 14033 Caen, France; Université de Caen Normandie, 14000 Caen, France
| |
Collapse
|
8
|
Algrin C, Golmard JL, Michallet M, Reman O, Huynh A, Perrot A, Sirvent A, Plesa A, Salaun V, Béné MC, Bories D, Tournilhac O, Merle-Béral H, Leblond V, Le Garff-Tavernier M, Dhedin N. Flow cytometry minimal residual disease after allogeneic transplant for chronic lymphocytic leukemia. Eur J Haematol 2017; 98:363-370. [PMID: 27943415 DOI: 10.1111/ejh.12836] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/28/2016] [Indexed: 01/12/2023]
Abstract
OBJECTIVES This study investigates whether achieving complete remission (CR) with undetectable minimal residual disease (MRD) after allogeneic stem cell transplantation (allo-SCT) for chronic lymphocytic leukemia (CLL) affects outcome. METHODS We retrospectively studied 46 patients transplanted for CLL and evaluated for post-transplant MRD by flow cytometry. RESULTS At transplant time, 43% of the patients were in CR, including one with undetectable MRD, 46% were in partial response, and 11% had refractory disease. After transplant, 61% of the patients achieved CR with undetectable MRD status. By multivariate analysis, reaching CR with undetectable MRD 12 months after transplant was the only factor associated with better progression-free survival (P = 0.02) and attaining undetectable MRD, independently of the time of negativity, was the only factor that correlated with better overall survival (P = 0.04). CONCLUSION Thus, achieving undetectable MRD status after allo-SCT for CLL is a major goal to improve post-transplant outcome.
Collapse
Affiliation(s)
- Caroline Algrin
- Hématologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.,Sorbonne Universités, UPMC Univ Paris 06, GRC n°11, GRECHY, Paris, France
| | - Jean-Louis Golmard
- Unité de Recherche Clinique, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
| | | | | | - Anne Huynh
- Hématologie, CHU de Toulouse, Toulouse, France
| | | | | | - Adriana Plesa
- Laboratoire d'Hématologie, CHU E. Herriot, Lyon, France
| | | | | | | | | | - Hélène Merle-Béral
- Laboratoire d'Hématologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
| | - Véronique Leblond
- Hématologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.,Sorbonne Universités, UPMC Univ Paris 06, GRC n°11, GRECHY, Paris, France
| | | | - Nathalie Dhedin
- Hématologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.,Unité d'Hématologie Adolescents Jeunes Adultes, Hôpital Saint-Louis, Paris, France
| |
Collapse
|
9
|
Chantepie SP, Parienti JJ, Salaun V, Benabed K, Cheze S, Gac AC, Johnson-Ansah H, Macro M, Damaj G, Vilque JP, Reman O. The prognostic value of hematogones in patients with acute myeloid leukemia. Am J Hematol 2016; 91:566-70. [PMID: 26934680 DOI: 10.1002/ajh.24350] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2016] [Revised: 02/25/2016] [Accepted: 02/29/2016] [Indexed: 11/09/2022]
Abstract
In acute myeloid leukemia (AML), new prognostic tools are needed to assess the risk of relapse. Hematogones (HGs) are normal B-lymphocyte precursors that increase in hematological diseases and may influence remission duration in AML. HG detection was prospectively investigated in 262 AML patients to determine its prognostic value. Flow cytometric HG detection was performed in bone marrow aspiration after intensive chemotherapy at the time of hematological recovery. Patients with HGs in bone marrow samples had a significantly better relapse-free survival (RFS) and overall survival (OS) than patients without HGs (P = 0.0021, and P = 0.0016). Detectable HGs independently predicted RFS (HR = 0.61, 95%CI: 0.42 - 0.89, P = 0.012) and OS (HR = 0.59, 95%CI: 0.38 - 0.92, 0.019) controlling for age, ELN classification, the number of chemotherapy cycles to achieve CR, performance status, secondary AML and flow cytometric minimal residual disease (MRD). In intensively treated AML, individual determination of HGs could be useful to stratify the optimal risk-adapted therapeutic strategy after induction chemotherapy. Am. J. Hematol. 91:566-570, 2016. © 2016 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
| | - Jean-Jacques Parienti
- Department of Biostatistics and Clinical Research; CHU Caen, Cote de Nacre Avenue; 14000 France
- Caen Normandie University, Medical school; Caen F-14000 France
| | - Véronique Salaun
- Hematology Laboratory; CHU Caen, Cote de Nacre Avenue; 14000 France
| | - Khaled Benabed
- Department of Hematology; CHU Caen, Cote de Nacre Avenue; 14000 France
| | - Stéphane Cheze
- Department of Hematology; CHU Caen, Cote de Nacre Avenue; 14000 France
| | - Anne-Claire Gac
- Department of Hematology; CHU Caen, Cote de Nacre Avenue; 14000 France
| | | | - Margaret Macro
- Department of Hematology; CHU Caen, Cote de Nacre Avenue; 14000 France
| | - Gandhi Damaj
- Department of Hematology; CHU Caen, Cote de Nacre Avenue; 14000 France
- Caen Normandie University, Medical school; Caen F-14000 France
| | - Jean-Pierre Vilque
- Department of Hematology; Baclesse Cancer Centre; Caen, General Harris Avenue 14000 France
| | - Oumedaly Reman
- Department of Hematology; CHU Caen, Cote de Nacre Avenue; 14000 France
| |
Collapse
|
10
|
de Boysson H, Lechapt-Zalcman E, Salaun V, Johnson A, Auzary C, Geffray L. Biopsy-proven muscular involvement of lymphomatoid granulomatosis assessed by (18)FDG-PET Scan. Joint Bone Spine 2015; 82:372-3. [PMID: 25623523 DOI: 10.1016/j.jbspin.2014.12.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2014] [Accepted: 12/04/2014] [Indexed: 10/24/2022]
Affiliation(s)
- Hubert de Boysson
- Department of Internal Medicine, centre hospitalier Robert-Bisson, 4, rue Roger-Aini, 14100 Lisieux, France; Department of Internal Medicine, centre hospitalier et universitaire de la Côte-de-Nacre, Caen, France.
| | | | - Véronique Salaun
- Hematology laboratory, centre hospitalier et universitaire de la Côte-de-Nacre, Caen, France
| | - Alison Johnson
- Department of Internal Medicine, centre hospitalier Robert-Bisson, 4, rue Roger-Aini, 14100 Lisieux, France
| | - Christophe Auzary
- Department of Internal Medicine, centre hospitalier Robert-Bisson, 4, rue Roger-Aini, 14100 Lisieux, France
| | - Loïk Geffray
- Department of Internal Medicine, centre hospitalier Robert-Bisson, 4, rue Roger-Aini, 14100 Lisieux, France
| |
Collapse
|
11
|
Tesnière AM, Morello R, Comoz F, Lecot S, Salaun V, Verneuil L. Pratique de la cytométrie en flux sur peau dans les lymphomes cutanés T épidermotropes et érythrodermiques : un outil diagnostique ? Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.09.097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
12
|
Audemard A, Lamy T, Bareau B, Sicre F, Suarez F, Truquet F, Salaun V, Macro M, Verneuil L, Lobbedez T, Castrale C, Boutemy J, Cheze S, Geffray L, Schleinitz N, Rey J, Lazaro E, Guillevin L, Bienvenu B. Vasculitis associated with large granular lymphocyte (LGL) leukemia: presentation and treatment outcomes of 11 cases. Semin Arthritis Rheum 2014; 43:362-6. [PMID: 24326032 DOI: 10.1016/j.semarthrit.2013.07.002] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2013] [Revised: 07/01/2013] [Accepted: 07/08/2013] [Indexed: 11/18/2022]
Abstract
OBJECTIVE The association between vasculitis and large granular lymphocyte (LGL) leukemia has rarely been reported or investigated. Thus, we assessed the clinical and biological phenotypes of LGL leukemia associated with vasculitis. RESULTS We studied a series of 11 patients displaying LGL leukemia associated with vasculitis (LAV). The mean age at diagnosis of LGL leukemia was 60.3 years; there were nine women and two men. The mean follow-up period was 45 months. The main LGL lineage was T-LGL (10 patients), and only one NK-LGL was identified. Clinical and biological features of T-LGL leukemia were compared with those from the 2009 French T-LGL registry. We did not find any relevant differences except that patients with LAV were predominantly female (p < 0.05). The most frequently observed vasculitis was cryoglobulinemia (n = 5). Three patients presented with cutaneous leukocytoclastic angiitis, two patients had ANCA-negative microscopic polyangiitis, and one patient had giant cell arteritis. The main clinical features involved the skin, e.g., purpura (91%), arthralgia (37%), peripheral neuritis (27%), and renal glomerulonephritis (18%). The most frequent histologic finding was leucocytoclastic vasculitis (54%). The rate of complete remission was high; i.e., 80%. A minority of patients had a vasculitis relapse (27%). Three patients (27%) died; one death was related to LGL leukemia (acute infection) and the two other deaths were related to vasculitis (both with heart failure). CONCLUSION We conclude that vasculitis is overrepresented in the population of LGL patients, LAV predominantly affects women, vasculitis preferentially affects the small vessels, and LAV has high rate of complete response.
Collapse
|
13
|
Tesnière A, Comoz F, Salaun V, Verneuil L. Pratique de la cytométrie en flux sur peau dans les lymphomes T cutanés épidermotropes et érythrodermiques : un outil diagnostique ? Ann Dermatol Venereol 2014. [DOI: 10.1016/j.annder.2014.04.163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
14
|
Chuffart M, Stephan A, Comoz F, Salaun V, Baldolli A, Reman O, Verneuil L. [Intravascular large B-cell lymphoma]. Ann Dermatol Venereol 2013; 140:328-30. [PMID: 23567238 DOI: 10.1016/j.annder.2013.02.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2013] [Accepted: 02/05/2013] [Indexed: 11/24/2022]
Affiliation(s)
- M Chuffart
- Service de dermatologie, CHU, 14, avenue Georges-Clémenceau, 14033 Caen, France.
| | | | | | | | | | | | | |
Collapse
|
15
|
Brugière C, Stefan A, Dompmartin A, Salaun V, Comoz F, Chantepie S, Campbell K, Verneuil L. Des lésions comédoniennes agressives : deux cas de mycosis fongoïde folliculotrope non transformé avec localisation pulmonaire. Ann Dermatol Venereol 2013. [DOI: 10.1016/j.annder.2013.01.397] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
16
|
Audemard A, Lamy T, Boutemy J, Lazaro E, Geffray L, Schleinitz N, Salaun V, Guillevin L, Bienvenu B. Vascularites associées à des leucémies à grands lymphocytes granuleux (LGL) : à propos d’une série rétrospective de 11 patients. Rev Med Interne 2012. [DOI: 10.1016/j.revmed.2012.10.052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
17
|
Brugière C, Stefan A, Dompmartin A, Salaun V, Comoz F, Verneuil L. Agressivité de deux cas de mycosis fongoïde folliculotrope non transformé avec localisation pulmonaire. Ann Dermatol Venereol 2012. [DOI: 10.1016/j.annder.2012.10.463] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
18
|
Ugo V, Leporrier N, Salaun V, Letestu R, Radford-Weiss I, Ramond S, Nataf J, Guesnu M, Picard F, Brouzes C, Perrot JY, Valensi F, Levy V, Ajchenbaum-Cymbalista F, Troussard X. Deciphering leukemic B-cell chronic lymphoproliferative disorders. Leuk Lymphoma 2009; 47:2088-95. [PMID: 17071481 DOI: 10.1080/10428190600727939] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Diagnosis of leukemic B-cell chronic lymphoproliferative disorders (B-CLPD) is a frequent challenge in hematology. In this multicentric study, we prospectively studied 165 new consecutive leukemic patients with B-CLPD selected on the basis of Royal Marsden Hospital scoring system < or =3. The primary aim of the study was to try to decipher the atypical cases and identify homogenous subgroups. Overall, morphological examination contributed to diagnosis in only 20% cases, all of them CD5 negative. Thirty additional cases were CD5 negative suggestive of leukemic marginal zone lymphoma in most cases. The significantly poorer survival of the 26 cyclin D1 positive cases justifies recommending its systematic determination among atypical B-CLPD. CD20 expression segregated clearly two subgroups among CD5 positive cyclin D1 negative B-CLPD. The 17 patients with the CD20 dim profile represent a homogeneous subgroup very close to typical B-cell chronic lymphocytic leukemia (B-CLL) on morphological, phenotypical and cytogenetical criteria. In contrast, the subgroup of 51 patients with a CD20 bright profile is heterogeneous. Their significantly lower p27 expression level suggest the presence of a proliferative component, underlying a more aggressive disease. Further genomic studies are warranted to establish their precise nature. These cases should not be included in the same therapeutic trials as B-CLL.
Collapse
Affiliation(s)
- Valérie Ugo
- Laboratoire d'Hématologie, CHU Brest, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Garnache-Ottou F, Feuillard J, Ferrand C, Biichle S, Trimoreau F, Seilles E, Salaun V, Garand R, Lepelley P, Maynadié M, Kuhlein E, Deconinck E, Daliphard S, Chaperot L, Beseggio L, Foisseaud V, Macintyre E, Bene MC, Saas P, Jacob MC. Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. Br J Haematol 2009; 145:624-36. [PMID: 19388928 DOI: 10.1111/j.1365-2141.2009.07679.x] [Citation(s) in RCA: 127] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
The diagnosis of plasmacytoid dendritic cell leukaemia (pDCL) is based on the immunophenotypic profile: CD4(+) CD56(+) lineage(neg) CD45RA(+)/RO(neg) CD11c(neg) CD116(low) CD123(+) CD34(neg) CD36(+) HLA-DR(+). Several studies have reported pDCL cases that do not express this exact profile or expressing some lineage antigens that could thus be misdiagnosed. This study aimed to validate pDCL-specific markers for diagnosis by flow-cytometry or quantitative reverse transcription polymerase chain reaction on bone marrow samples. Expression of markers previously found in normal pDC was analysed in 16 pDCL, four pDCL presenting an atypical phenotype (apDCL) and 113 non-pDC - lymphoid or myeloid - acute leukaemia. CD123 was expressed at significantly higher levels in pDCL and apDCL. BDCA-2 was expressed on 12/16 pDCL and on 2/4 apDCL, but was never detected in the 113 non-pDC acute leukaemia cases. BDCA-4 expression was found on 13/16 pDCL, but also in 12% of non-pDC acute leukaemia. High levels of LILRA4 and TCL1A transcripts distinguished pDCL and apDCL from all other acute leukaemia (except B-cell acute lymphoblastic leukaemia for TCL1A). We thus propose a diagnosis strategy, scoring first the CD4(+) CD56(+/-) MPO(neg) cCD3(neg) cCD79a(neg) CD11c(neg) profile and then the CD123(high), BDCA-2 and BDCA-4 expression. Atypical pDCL can be also identified this way and non-pDC acute leukaemia excluded: this scoring strategy is useful for diagnosing pDCL and apDCL.
Collapse
Affiliation(s)
- Francine Garnache-Ottou
- INSERM UMR645, Université of Franche-Comté, Etablissement Français du Sang Bourgogne Franche-Comté, 1 boulevard A. Fleming, Besançon, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Garnache-Ottou F, Chaperot L, Biichle S, Ferrand C, Remy-Martin JP, Deconinck E, de Tailly PD, Bulabois B, Poulet J, Kuhlein E, Jacob MC, Salaun V, Arock M, Drenou B, Schillinger F, Seilles E, Tiberghien P, Bensa JC, Plumas J, Saas P. Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. Blood 2004; 105:1256-64. [PMID: 15388576 DOI: 10.1182/blood-2004-06-2416] [Citation(s) in RCA: 66] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
A new entity of acute leukemia coexpressing CD4(+)CD56(+) markers without any other lineage-specific markers has been identified recently as arising from lymphoid-related plasmacytoid dendritic cells (pDCs). In our laboratory, cells from a patient with such CD4(+)CD56(+) lineage-negative leukemia were unexpectedly found to also express the myeloid marker CD33. To confirm the diagnosis of pDC leukemia despite the CD33 expression, we demonstrated that the leukemic cells indeed exhibited pDC phenotypic and functional properties. In 7 of 8 other patients with CD4(+)CD56(+) pDC malignancies, we were able to confirm that the tumor cells expressed CD33 although with variable expression levels. CD33 expression was shown by flow cytometry, reverse transcriptase-polymerase chain reaction, and immunoblot analysis. Furthermore, CD33 monoclonal antibody stimulation of purified CD4(+)CD56(+) leukemic cells led to cytokine secretion, thus confirming the presence of a functional CD33 on these leukemic cells. Moreover, we found that circulating pDCs in healthy individuals also weakly express CD33. Overall, our results demonstrate that the expression of CD33 on CD4(+)CD56(+) lineage-negative cells should not exclude the diagnosis of pDC leukemia and underline that pDC-specific markers should be used at diagnosis for CD4(+)CD56(+) malignancies.
Collapse
Affiliation(s)
- Francine Garnache-Ottou
- Etablissement Français du Sang Bourgogne Franche-Comté, Unité mixte EFS/Université EA2284/Inserm U645, IFR133, Besançon, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Chaperot L, Perrot I, Jacob MC, Blanchard D, Salaun V, Deneys V, Lebecque S, Brière F, Bensa JC, Plumas J. Leukemic plasmacytoid dendritic cells share phenotypic and functional features with their normal counterparts. Eur J Immunol 2004; 34:418-26. [PMID: 14768046 DOI: 10.1002/eji.200324531] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
This work aims to further characterize the newly described leukemic plasmacytoid dendritic cells (LPDC), for which we had previously demonstrated their normal, PDC-like ability to produce IFN-alpha. In addition, LPDC also express the specific antigens BDCA-2 and BDCA-4. Importantly, they become fully competent antigen-presenting cells (APC) after a short maturation induced by IL-3 + CD40L or virus, exhibiting a characteristic APC phenotype (high expression of CD83 and of the costimulatory molecules CD40, CD80, CD86). Whereas IL-3 + CD40L-activated LPDC prime naive CD4(+) T cells towards a Th2 pathway (IL-4-secreting T cells), virus-activated LPDC drive a Th1 profile (IFN-gamma-secreting T cells). Moreover, we show in one case that LPDC are able to capture, process and present exogenous antigens, leading to the activation of both CD4(+) and CD8(+) T cell clones in an antigen-specific manner. This study further characterizes the phenotype and immunological functions of LPDC.
Collapse
Affiliation(s)
- Laurence Chaperot
- Department of Research and Development, EFS Rhône-Alpes Grenoble, La Tronche, France.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Penven K, Macro M, Salaun V, Comoz F, Reman O, Leroy D, Troussard X, Petrella T, Dompmartin A. Skin manifestations in CD4+, CD56+ malignancies. Eur J Dermatol 2003; 13:161-5. [PMID: 12695132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/01/2023]
Abstract
CD4+ CD56+ hematologic neoplasms were recently individualized. We report three cases of CD4+ CD56+ malignancies with cutaneous lesions in three cases and also bone marrow involvement in two cases. Two patients relapsed 2 and 3 months after polychemotherapy. Two patients died within 3-10 months. A constant immunophenotype was observed with the co-expression of CD4 and CD56, the absence of B and T-cell markers. The salient fact of this report is the presence of T-cell clonal rearrangement. The clinical and pathological features closely resemble the specific cutaneous manifestations in acute leukemia with monocytic differentiation, especially the granulocytic sarcoma. Because of the positivity of the CD56, natural killer cell proliferations were discussed. Since 1994, 50 cases of CD4+, CD56+ cutaneous neoplasms have been reported with specific clinical, cytologic and immunohistochemical features. The diagnosis is more difficult when the cutaneous location is exclusive; on the contrary, the cytological features of the blood and medullar cells with cytoplasmic vacuoles and pseudopodia are characteristic of this hematologic neoplasm. The presence of CD123 antigen in most of the cases is an argument for a plasmacytoid dendritic cell proliferation and it is also a good marker for primary cutaneous lesions.
Collapse
Affiliation(s)
- Katell Penven
- Department of Dermatology, Centre Hospitalier Universitaire, Avenue Georges Clemenceau, 14033 Caen Cedex, France
| | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Cheze S, Musafiri D, Reman O, Macro M, Salaun V, Leporrier M, Troussard X. Chemiluminescence: a test for predicting hematopoietic recovery after autologous or allogeneic bone marrow transplantation. Eur J Haematol 1999; 63:272-3. [PMID: 10530418 DOI: 10.1111/j.1600-0609.1999.tb01890.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|